Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

MannKind Corporation logoMannKind Corporation

MNKD · Nasdaq · USD · Market cap $1.3B · 591 employees

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.

FAIL · Does not pass the screen
3.85 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price3.85 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.11)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $4.50 to $6.59, base estimate $5.73 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders insiders sold, $128,478, latest filing 2026-09-25
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.11, read 2026-11-18
  • Ethical does not pass the values gate
Price3.85 USD
Fair value5.73
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup4.19-8.1% to today Distribution gives way to Markup after a 13% rise in 5 weeks
2026-10-11Read Distribution3.71+3.8% to today Markdown gives way to Distribution after a 6% rise in 9 days
2026-10-02Read Markdown3.50+10.0% to today Markup gives way to Markdown
2026-07-02Read Markup3.66+5.2% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

MannKind Corporation holds its Markup at $3.85. Consolidating, no directional conviction, held for 16 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 16 days
Price at the screen$3.85
ValuationN/A trailing · 25.08 forward price to earnings
Values screenFAIL · score 70.0
Beta1.09
The Workings

Five Screens: MNKD's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 46.38% Below 33% Fail
Interest-bearing cash 0.63% Below 33% Pass
Receivables 14.30% Below 49% Pass
Revenue purity 2.31% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

MannKind's business is in a permissible area, but its interest-bearing debt is about 46% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when MNKD's ethical verdict changes

Today MNKD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 33% discount to our $5.73 fair value, 24.00% revenue growth.

Method.

4.50Conservative5.73Base case6.59Growth case 3.85Price

USD, 2026-11-20 screen. A 32.8% under base.

The Street's Range
5.00Street low 8.00Street average 13.00Street high 3.85Price

Street: 9 covering, consensus Strong Buy. Average target +108%.

Chart
The Business, in Plain Words

Biotech chasing diabetes relief still burns cash

Imagine a patient managing diabetes who needs reliable new treatments. MannKind develops options for that and other chronic conditions, yet it still reports a negative profit margin of 7 percent despite 15 percent revenue growth. With an unknown moat and an opportunity rating of none, the business does not clear our bar even though the ethical screen returns a pass.

The forward price to earnings sits at 20.9 times while eight analysts carry a strong buy consensus and a median target of 7 dollars against the current 4.03 dollar price. Our own fair value of 5.29 dollars implies some headroom, but the absence of a clear competitive edge leaves the story too thin to justify a position.

High execution risk remains the core issue in a field where late stage setbacks can erase years of progress. The numbers show promise on paper, yet without proven durability the setup stays speculative. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E25.1xfairly priced for its growth rate
EPS, trailing-0.24
EPS, forward0.16
Revenue growth+24.0%strong top-line growth
Profit margin-18.1%currently unprofitable
FCF yield-0.47%
Current ratio2.22comfortably covers its short-term bills
Beta1.09moves a little more than the market
Short interest, float0.08%
52-week range2.23 - 6.51
Market cap$1.3B
Employees591

MNKD-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $3.95 -2.9% Entry 21
2026-11-19 Markup $4.07 -2.9% Entry 20
2026-11-12 Markup · changed $4.19 +6.6% Entry 19

The framework has shifted from distribution to markup since the last review.

2026-11-05 Distribution $3.93 +5.4% Entry 18
2026-11-04 Distribution $3.73 +6.6% Entry 17
2026-11-03 Distribution $3.50 +0.0% Entry 16
2026-11-02 Distribution $3.50 +0.0% Entry 15
2026-11-01 Distribution $3.50 +9.7% Entry 14
2026-10-31 Distribution $3.19 +0.0% Entry 13
2026-10-30 Distribution $3.19 +0.0% Entry 12

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on MNKD

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in MNKD's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · MNKD
DateInsiderTitleTypeSharesValue
2026-09-25 Binder Steven B. Dir S - Sale 39,051 $128,478
2026-09-10 Binder Steven B. Dir S - Sale 33,558 $127,856

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $3.36 +7.0% · $1,070 +7.0%
2 months $2.57 +39.9% · $1,399 +39.9%
3 months $2.82 +27.5% · $1,275 +27.5%
6 months $5.81 -38.1% · $619 -38.1%
1 year $3.92 -8.3% · $917 -8.3%
2 years $4.49 -19.9% · $801 -19.9%
3 years $4.03 -10.8% · $892 -10.8%
5 years $4.05 -11.2% · $888 -11.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever MNKD does next, these words stay.

MannKind Corporation · MNKD · Markup · $3.85
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.